In this study, we used the related target proteins of NAFLD as reference materials, involving NF-α [11], IL-6, and PPAR-α [12], and used network pharmacology and molecular docking technology to explore the mechanism of QHD in the treatment of NAFLD, so as to provide a scientific basis for clinical application. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.